"NAMALWA人Burkitt's淋巴瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：懸浮生長

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點(diǎn)、生長速率、鋪板效率、生長條件和生長特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長的快速生長細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實(shí)驗(yàn)室環(huán)境中長期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個容器轉(zhuǎn)移到另一個容器的過程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補(bǔ)充新鮮培養(yǎng)基；凍存則是為了長期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長。

換液周期：每周2-3次

HFL 1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：MIA Paca2細(xì)胞、Panc 04.03細(xì)胞、HCC-1937細(xì)胞

L929(NCTC) Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：C-26細(xì)胞、GP-293細(xì)胞、AHH1細(xì)胞

D10G41 Cells;背景說明：T淋巴細(xì)胞；AKR/J;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SUM-102細(xì)胞、AR4IP細(xì)胞、bEnd3細(xì)胞

背景信息：最初是從一名患有Burkitt's淋巴瘤的患者的腫瘤組織中分離出來的。是一種高度惡性的B細(xì)胞淋巴瘤，常見于兒童和年輕人。有EB病毒基因組。

NAMALWA人Burkitt's淋巴瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

貼壁細(xì)胞的傳代培養(yǎng)，詳細(xì)步驟如下：首先倒掉培養(yǎng)基，在這一步驟可以收集一些細(xì)胞上清做支原體檢測；加入胰蛋白酶，一般T25是加2mL，蓋好瓶蓋，搖晃T25培養(yǎng)瓶，使胰蛋白酶均勻覆蓋在細(xì)胞表面，放入培養(yǎng)箱2-3min，期間可在顯微鏡下觀察，看到大部分細(xì)胞變圓，即可放入超凈臺，加入2倍的完全培養(yǎng)基，這里就是加4mL培養(yǎng)基，終止消化；將含有胰蛋白酶，細(xì)胞和培養(yǎng)基一起轉(zhuǎn)移到離心管中，1000rpm/3min離心，去掉上清；新鮮的完全培養(yǎng)基重懸，根據(jù)細(xì)胞的生長特性和后續(xù)的實(shí)驗(yàn)需求進(jìn)行傳代，比如我養(yǎng)的Hepa1-6就長的比較快，不是著急用的話，我就會按1E6個細(xì)胞/T75培養(yǎng)瓶進(jìn)行傳代；但如果后兩天要用，就會適當(dāng)多傳一點(diǎn)；還可通過顯微鏡計(jì)數(shù)后，直接用于細(xì)胞鋪板，繼續(xù)后續(xù)的實(shí)驗(yàn)。

Tissue Culture-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CA-46細(xì)胞、HCC1419細(xì)胞、WC00059細(xì)胞

KBM-5 Cells;背景說明：慢性髓白血??；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BPH-1細(xì)胞、University of Michigan-Urothelial Carcinoma-1細(xì)胞、Oregon J-111細(xì)胞

SH-SY5Y Cells;背景說明：據(jù)報道，該細(xì)胞的密度可高達(dá)１×１０６cells/cm２，具有中等水平的多巴胺β羥化酶的活性。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HMEC1細(xì)胞、COR L279細(xì)胞、ES-2細(xì)胞

AJ60 Cells(提供STR鑒定圖譜)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

物種來源：人源、鼠源等其它物種來源

NAMALWA人Burkitt's淋巴瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

形態(tài)特性：淋巴母細(xì)胞樣

貼壁細(xì)胞消化傳代時通常采用兩種方法：一、加入胰酶等細(xì)胞脫落后，再加培養(yǎng)基中止胰酶作用，離心傳代；二、加入胰酶后，鏡下觀察待細(xì)胞始脫落時，棄胰酶，加培養(yǎng)分瓶。但前者太麻煩，而后者有可能對細(xì)胞施加胰酶選擇，因?yàn)榭偸琴N壁不牢的細(xì)胞先脫落，對腫瘤細(xì)胞來說，這部分細(xì)胞有可能是惡性程度較GAO的細(xì)胞亞群。一種簡單的消化傳代方法。加入PBS洗去血清或加入胰酶先中和血清的作用(３０s)，棄之，再加入適量胰酶作用１０s-４０s(根據(jù)細(xì)胞消化的難易程度)，棄之，這樣依賴殘余的胰酶就可將細(xì)胞消化單細(xì)胞。對于較難消化的細(xì)胞，可以用２%利多卡因消化５-８分鐘，然后再棄去，加培養(yǎng)基吹打也可以，對細(xì)胞的影響不大。不用PBS也不用Hanks洗，只要把舊培養(yǎng)吸的干凈一點(diǎn)，直接加酶消化應(yīng)該不會有什么問題。棄培養(yǎng)后，用０.０４%的EDA沖洗一次，再用１/４v的０.０４%的EDA室溫孵育５min，棄取大部分EDA，加入與剩余EDA等量的胰酶(預(yù)熱)總體積１/１０v。消化到有細(xì)胞脫落。不過有人說EDA對細(xì)胞不HAO，有證據(jù)嗎？培養(yǎng)的BASMC：倒掉舊培養(yǎng)加入少量胰酶沖一下，倒掉再加入０.１２５-０.２５%胰酶約６-１０滴或１ml(２５ml bole)消化再加入適量新培養(yǎng)基中和，并分瓶這種方法簡單、省事；效果很HAO并且不損失細(xì)胞！

INS-1 Cells;背景說明：該細(xì)胞源自X射線照射的移植胰島瘤的大鼠，胰島素陽性，可合成胰島素原I和II，可用于beta細(xì)胞功能研究。;傳代方法：１：３—１：６傳代，每周換液２—３次;生長特性：貼壁生長;形態(tài)特性：不規(guī)則，多角;相關(guān)產(chǎn)品有：BALL1細(xì)胞、22Rv1細(xì)胞、COLO 206細(xì)胞

RPMI8226/S Cells;背景說明：來源于一位６１歲的男性漿細(xì)胞瘤患者；可產(chǎn)生免疫球蛋白輕鏈，未檢測到重鏈。;傳代方法：按１：２傳代，５-６小時可以看到細(xì)胞分裂;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HFL-1細(xì)胞、SMA-560細(xì)胞、BEL7404細(xì)胞

Hepa-RG Cells;背景說明：肝癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SF 763細(xì)胞、DHL4細(xì)胞、NCIH1373細(xì)胞

CCD 966 SK Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A2780 CP70細(xì)胞、149PT細(xì)胞、BE2-C細(xì)胞

H522 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HUASMC細(xì)胞、JHH-2細(xì)胞、Daudi細(xì)胞

PLMVEC Cells;背景說明：肺微血管；內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：JB6 clone 30, subclone 7b細(xì)胞、HTh-74細(xì)胞、L(TK-)細(xì)胞

Tadarida brasiliensis 1 lung Cells;背景說明：肺;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：JCA-1細(xì)胞、SCC15細(xì)胞、P30/OHK細(xì)胞

P30/OHK Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１０^５ cells/６０mm dish;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：WSU-HN13細(xì)胞、LCD細(xì)胞、PAEC細(xì)胞

M619 Cells;背景說明：脈絡(luò)膜黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H498細(xì)胞、PC-10細(xì)胞、UM-RC-2細(xì)胞

C17.2 Cells;背景說明：神經(jīng)干細(xì)胞；C５７BL/６ x CD-１;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U 138 MG細(xì)胞、Eca109細(xì)胞、U266S細(xì)胞

H-2228 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，每周２-３次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：VB細(xì)胞、KE-39細(xì)胞、KP-N-RT-BM細(xì)胞

SNU-638 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hu-P-T4細(xì)胞、VeroC1008細(xì)胞、Anip[973]細(xì)胞

DSL6A/C1 Cells;背景說明：胰腺癌；雄性；Lewis;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HSC-4細(xì)胞、SW 900細(xì)胞、LK-2細(xì)胞

hESC Cells;背景說明：子宮內(nèi)膜；間質(zhì)細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BCAP37細(xì)胞、TE12細(xì)胞、174xCEM.T2細(xì)胞

CNE2Z Cells;背景說明：鼻咽癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LOU-NH-91細(xì)胞、COS-1細(xì)胞、CNE細(xì)胞

138MG Cells;背景說明：星形細(xì)胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TYKnu細(xì)胞、HEK293-EBNA1細(xì)胞、DrG細(xì)胞

HEK293-EBNA Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Panc 2.03細(xì)胞、Hs746T細(xì)胞、U-937細(xì)胞

Abcam A-549 TMEM64 KO 2 Cells(提供STR鑒定圖譜)

AG02655 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line CSH727 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RST011 Cells(提供STR鑒定圖譜)

BEAS-2B/EJ-ras Cells(提供STR鑒定圖譜)

CHO-MCHR2 Cells(提供STR鑒定圖譜)

DA02876 Cells(提供STR鑒定圖譜)

ES[MC1R(20):tetJarid2(37)] Cells(提供STR鑒定圖譜)

GM06548 Cells(提供STR鑒定圖譜)

SK HEP 01 Cells;背景說明：SK-HEP-１細(xì)胞系已被鑒定為內(nèi)皮來源。該細(xì)胞系為異倍體女性人（XX），染色體在亞三倍體范圍內(nèi)。在裸鼠中，它能形成與肝癌相一致的大細(xì)胞癌;傳代方法：１：３傳代，２-３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HcaF細(xì)胞、Wien-133細(xì)胞、CAMA-1細(xì)胞

T-47-D Cells;背景說明：浸潤性導(dǎo)管癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BTI-TN5B1-4細(xì)胞、Panc_08_13細(xì)胞、KMST6細(xì)胞

Hs 746.T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK_N_BE2C細(xì)胞、U87 MG細(xì)胞、Pt K2 (NBL-5)細(xì)胞

NMCG-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：GM00215細(xì)胞、TE-32細(xì)胞、CAL 62細(xì)胞

CV 1 Cells;背景說明：CV-１細(xì)胞株是１９６４年由JensenFC等建系的，源自成年雄性非洲綠猴腎，被用于Rous肉瘤病毒的轉(zhuǎn)染研究?？勺鳛镾V４０載體的轉(zhuǎn)染宿主。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：hADSCs細(xì)胞、BALL-1細(xì)胞、Z310細(xì)胞

Hs821T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：ATC241細(xì)胞、HCC2279細(xì)胞、MZ-CRC-1細(xì)胞

OCILY3 Cells;背景說明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Madison細(xì)胞、mouse Inner Medullary Collecting Duct-3細(xì)胞、HEK AD293細(xì)胞

Mouse Bladder Tumor line-2 Cells;背景說明：膀胱移行細(xì)胞癌；C３H/He;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NPA87-1細(xì)胞、Porcine Kidney-15細(xì)胞、IPLB-SF-21細(xì)胞

NAMALWA人Burkitt's淋巴瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

E304 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SR-786細(xì)胞、3LL細(xì)胞、U138細(xì)胞

WM115 Cells;背景說明：黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NE1細(xì)胞、SN12PM6細(xì)胞、Jurkat FHCRC細(xì)胞

Mv1Lu Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：P3X63-Ag8.653細(xì)胞、KU-812細(xì)胞、BIU-87細(xì)胞

MDA-MB-435-S Cells;背景說明：MDA-MB-４３５S是一種紡錘形的細(xì)胞，１９７６年由其親本(４３５)中篩選得到。４３５是從３１歲的轉(zhuǎn)移性乳腺導(dǎo)管腺癌女性患者胸水中分離得到。當(dāng)用熒光染料對微管蛋白進(jìn)行染色時親本細(xì)胞顯現(xiàn)散布特征(II型)。最近通過cDNA陣列研究表明，親本(MDA-MB-４３５)可歸入黑素瘤起源。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：紡錘形;相關(guān)產(chǎn)品有：Kit225-K6細(xì)胞、NTERA2D1細(xì)胞、Hs 737.T細(xì)胞

PA I Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２-３次?！?生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：GM00637H細(xì)胞、P3J.HR1K細(xì)胞、EU-2細(xì)胞

MDA-MB-157 Cells;背景說明：該細(xì)胞源自一位患有乳腺髓樣癌的４４歲黑人女性，表達(dá)WNT７B癌基因，細(xì)胞與細(xì)胞邊界處有細(xì)胞橋粒、微絨毛、張力細(xì)絲。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：A 172細(xì)胞、KGN細(xì)胞、LOUNH91細(xì)胞

LS 513 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：４傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H292細(xì)胞、Molm14細(xì)胞、XuanWei Lung Cancer-05細(xì)胞

GM11085 Cells(提供STR鑒定圖譜)

HAP1 CMTR1 (-) 2 Cells(提供STR鑒定圖譜)

Hs 888Lu Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Ramos 2G6 4C10細(xì)胞、KP2細(xì)胞、KYSE70細(xì)胞

RCC4 Cells;背景說明：腎透明細(xì)胞癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KM933細(xì)胞、NCI-SNU-423細(xì)胞、HEK 293-F細(xì)胞

RPMI No. 1846 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H2081細(xì)胞、MDA-MB-231 #4175細(xì)胞、SK-OV-3細(xì)胞

HOP 92 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WiDr/S細(xì)胞、624mel細(xì)胞、DI-TNC1細(xì)胞

ID8 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：IPI-2I細(xì)胞、RA 1細(xì)胞、FHs 74 Int細(xì)胞

B16-F0 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs737T細(xì)胞、AK細(xì)胞、HOEC細(xì)胞

H.Ep.-2 Cells;背景說明：最初認(rèn)為這個細(xì)胞源自喉上皮癌，但隨后通過同功酶分析、HeLa標(biāo)記染色體和DNA指紋分析發(fā)現(xiàn)，起源細(xì)胞已被HeLa污染。 角蛋白免疫過氧化物酶染色陽性。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SNU-886細(xì)胞、PLA802細(xì)胞、BT-B細(xì)胞

H69/P Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：４傳代，每周換液２次;生長特性：懸浮生長，聚團(tuán);形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：Mo 59J細(xì)胞、SNU-1040細(xì)胞、HFT-8810細(xì)胞

HG1943 Cells(提供STR鑒定圖譜)

IMR-32rDOX20 Cells(提供STR鑒定圖譜)

LXKC40 Cells(提供STR鑒定圖譜)

ND04385 Cells(提供STR鑒定圖譜)

PeCa-UkHb-01 Cells(提供STR鑒定圖譜)

Ubigene HeLa LIFR KO Cells(提供STR鑒定圖譜)

XLC050 Cells(提供STR鑒定圖譜)

HF2303 Cells(提供STR鑒定圖譜)

SU86-86 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-4細(xì)胞、S3 HeLa細(xì)胞、UPCI:SCC090細(xì)胞

NUGC-4 Cells;背景說明：胃癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：半貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WSU-DLCL-2細(xì)胞、CF-1 MEF細(xì)胞、Be-Wo細(xì)胞

CORL105 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HT-29細(xì)胞、Ontario Cancer Institute-Acute Myeloid Leukemia-3細(xì)胞、MDA-MB 361細(xì)胞

LK 2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MZ-CRC-1細(xì)胞、LADMAC細(xì)胞、J774 A1細(xì)胞

CaSki Cells;背景說明：這株細(xì)胞是從小腸腸系膜轉(zhuǎn)移灶的細(xì)胞中建立的。 據(jù)報道，它含有完整的HPV-１６(每個細(xì)胞大約６００個拷貝)和HPV-１８相關(guān)序列。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HSF2細(xì)胞、EL 4細(xì)胞、KMS26細(xì)胞

CaSki Cells;背景說明：這株細(xì)胞是從小腸腸系膜轉(zhuǎn)移灶的細(xì)胞中建立的。 據(jù)報道，它含有完整的HPV-１６(每個細(xì)胞大約６００個拷貝)和HPV-１８相關(guān)序列。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HSF2細(xì)胞、EL 4細(xì)胞、KMS26細(xì)胞

HL 60 Cells;背景說明：該細(xì)胞由CollinsSJ從一位患有急性早幼粒細(xì)胞性白血病的３６歲白人女性的外周血中分離建立；可自發(fā)分化，或在鹽、次黃嘌呤、佛波醇肉豆蔻酸(PMA,TPA)、DMSO(１%to１.５%)、D和視黃酸的刺激下發(fā)生分化；PMA刺激后可分泌TNF-α。該細(xì)胞具有吞噬活性和趨化反應(yīng)，癌基因myc陽性，表達(dá)補(bǔ)體受體和FcR。;傳代方法：維持細(xì)胞濃度在１×１０５-１×１０６/ml,每２-３天換液１次。;生長特性：懸浮生長;形態(tài)特性：髓母細(xì)胞樣;相關(guān)產(chǎn)品有：SW 948細(xì)胞、B-104細(xì)胞、RERFLCMS細(xì)胞

MAEC Cells;背景說明：主動脈；內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH820細(xì)胞、TF1細(xì)胞、RBL細(xì)胞

IGROV1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI.H226細(xì)胞、GH3細(xì)胞、SW982細(xì)胞

NR 8383 Cells;背景說明：NR８３８３(正常大鼠，１９８３年８月３日)來源于肺灌洗時的正常大鼠肺泡巨噬細(xì)胞。細(xì)胞在gerbil肺細(xì)胞連續(xù)培養(yǎng)液存在下培養(yǎng)了大約８-９個月。隨后，不再需要外源生長因子。通過有限稀釋法從單個細(xì)胞克隆并亞克隆NR８３８３細(xì)胞，并三次用軟瓊脂亞克隆。細(xì)胞表現(xiàn)出巨噬細(xì)胞的特性，吞噬酵母多糖和銅綠，非特異性脂酶活性，F(xiàn)c受體，氧化降解；分泌IL-１,TNFbeta和IL-６，可重復(fù)地響應(yīng)外源生長因子。NR８３８３細(xì)胞響應(yīng)博萊霉素，分泌TGFbeta前體。在博萊霉素刺激下，TGFbe;傳代方法：１：２傳代;生長特性：半貼壁生長;形態(tài)特性：巨噬細(xì)胞;相關(guān)產(chǎn)品有：RH-30細(xì)胞、SF 539細(xì)胞、PLC8024細(xì)胞

CCC-HHM-2 Cells;背景說明：心肌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CL40細(xì)胞、NCIH2171細(xì)胞、CCD19-Lu細(xì)胞

CCC-HEL-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SF763細(xì)胞、MDA.MB.231細(xì)胞、WM-266-mel細(xì)胞

H-596 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：８傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H-661細(xì)胞、CAL62細(xì)胞、Tb1Lu細(xì)胞

COLO684 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GP5d細(xì)胞、MDA134細(xì)胞、SNUC1細(xì)胞

Line 697 Cells;背景說明：B淋巴細(xì)胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HUT 226細(xì)胞、L-cells細(xì)胞、HeLa-S3細(xì)胞

SCVIi105-A Cells(提供STR鑒定圖譜)

H-1522 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KNS-42細(xì)胞、CAL-78細(xì)胞、Hs 766.T細(xì)胞

HcerEpic Cells;背景說明：子宮頸；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-596細(xì)胞、Hepa1-6細(xì)胞、hUC-MSC細(xì)胞

COLO 320 DM Cells;背景說明：該細(xì)胞可產(chǎn)生５-羥色胺、去甲、、ACTH和甲狀旁腺素。角蛋白、波形蛋白弱陽性。培養(yǎng)條件： RPMI １６４０  １０%FBS;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮+貼壁;形態(tài)特性：淋巴細(xì)胞;相關(guān)產(chǎn)品有：HT 1197.T細(xì)胞、WPMY1細(xì)胞、SK-MEL-2-LUC細(xì)胞

RS4:11 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周２-３次;生長特性：懸浮生長;形態(tài)特性：成淋巴細(xì)胞;相關(guān)產(chǎn)品有：PC-3/M細(xì)胞、Ramos (RA 1)細(xì)胞、COLO-394細(xì)胞

RGE Cells;背景說明：腎小球；內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs 683.T細(xì)胞、L615細(xì)胞、NOZC-1細(xì)胞

HSAEC1-KT Cells;背景說明：肺；HGNC-TERT轉(zhuǎn)化；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SW-403細(xì)胞、Duke University 4475細(xì)胞、H-1623細(xì)胞

LLCMK2 Cells;背景說明：胚胎；腎；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：L615細(xì)胞、Hs888Lu細(xì)胞、Hs_578t細(xì)胞

NCI-H82 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：５傳代，每周換液２-３次;生長特性：懸浮生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：VSC4.1細(xì)胞、PT67細(xì)胞、H2108細(xì)胞

NAMALWA人Burkitt's淋巴瘤細(xì)胞全年復(fù)蘇|已有STR圖譜

Hi-5 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC1438細(xì)胞、SNU-C2A細(xì)胞、As-PC1細(xì)胞

H-2195 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-226細(xì)胞、TALL1細(xì)胞、MV 4;11細(xì)胞

EFM-192A Cells;背景說明：乳腺癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H524細(xì)胞、C3H10T1/2 clone8細(xì)胞、ZYM-SVEC01細(xì)胞

OSC-19 Cells;背景說明：舌鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BE2_C細(xì)胞、HNE-3細(xì)胞、HCEpiC細(xì)胞

NT2D1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EJ-1細(xì)胞、OCI-Ly10細(xì)胞、H1755細(xì)胞

RC-4B/C Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-HUT-520細(xì)胞、Monomac-1細(xì)胞、SHEP1細(xì)胞

BayGenomics ES cell line RRI002 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XH413 Cells(提供STR鑒定圖譜)

ES[MC1R(20):tetSub1(12)] Cells(提供STR鑒定圖譜)

NAL1A clone C4E10 Cells(提供STR鑒定圖譜)

UC8-1B9 Cells(提供STR鑒定圖譜)

MC-B11/14 Cells(提供STR鑒定圖譜)

" "PubMed=170370; DOI=10.1099/0022-1317-28-2-207

Adams A., Strander H., Cantell K.

Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.

J. Gen. Virol. 28:207-217(1975)

PubMed=216485

Higgins N.P., Strauss B.S.

Differences in the ability of human lymphoblastoid lines to exclude bromodeoxyuridine and in their sensitivity to methyl methanesulfonate and to incorporated [3H]thymidine.

Cancer Res. 39:312-320(1979)

PubMed=464569; DOI=10.1128/AAC.15.3.420; PMCID=PMC352676

Klein F., Ricketts R.T., Jones W.I., DeArmon I.A., Temple M.J., Zoon K.C., Bridgen P.J.

Large-scale production and concentration of human lymphoid interferon.

Antimicrob. Agents Chemother. 15:420-427(1979)

PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x

Povey S., Jeremiah S., Arthur E., Steel M., Klein G.

Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.

Ann. Hum. Genet. 44:119-133(1980)

PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336

Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D., Parsons R.G.

Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.

J. Immunol. 129:1336-1342(1982)

PubMed=6811418; DOI=10.1016/S0171-2985(11)80031-8

Spira G., Koide N., Aman P., Ber R., Klein G.

Truncated mu chain in a Burkitt lymphoma line (P3HR-1) and its fate in various hemapoietic somatic cell hybrids.

Immunobiology 162:199-209(1982)

PubMed=6231253; DOI=10.1002/ijc.2910330407

Ehlin-Henriksson B., Klein G.

Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.

Int. J. Cancer 33:459-463(1984)

PubMed=2580922; DOI=10.1089/jir.1985.5.65

Feinstein S., Traub A., Lazar A., Mizrahi A., Teitz Y.

Studies on cell binding and internalization of human lymphoblastoid (Namalva) interferon.

J. Interferon Res. 5:65-76(1985)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.

Leuk. Res. 9:209-229(1985)

PubMed=2995175

Wurm F.M., Polastri G.D., Hilfenhaus J., Harth H., Zankl H.

Long term cultivation of Namalva cells for interferon production: stable cytogenetic markers for identification of cells in spite of drastic chromosomal variation.

Dev. Biol. Stand. 60:393-403(1985)

PubMed=2998993

Steel C.M., Morten J.E.N., Foster E.

The cytogenetics of human B lymphoid malignancy: studies in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell lines.

IARC Sci. Publ. 60:265-292(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).

Leuk. Res. 9:549-559(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.

Leuk. Res. 9:537-548(1985)

PubMed=3997900; DOI=10.1016/S0092-1157(85)80024-x

Whitaker A.M.

The chromosomes of the Namalwa cell line.

J. Biol. Stand. 13:173-175(1985)

PubMed=2415623; DOI=10.4049/jimmunol.136.1.320

Goldmacher V.S., Lambert J.M., Young A.Y., Anderson J., Tinnel N.L., Kornacki M., Ritz J., Blattler W.A.

Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines.

J. Immunol. 136:320-325(1986)

PubMed=3080238

Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.

Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.

Cancer Res. 46:1182-1188(1986)

PubMed=3100061; DOI=10.1016/0008-8749(86)90099-7

Benjamin D., Bazar L.S., Wallace B., Jacobson R.J.

Heterogeneity of B-cell growth factor receptor reactivity in healthy donors and in patients with chronic lymphatic leukemia: relationship to B-cell-derived lymphokines.

Cell. Immunol. 103:394-408(1986)

PubMed=3026973; DOI=10.1002/ijc.2910390215

Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.

Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.

Int. J. Cancer 39:211-218(1987)

PubMed=2830981; DOI=10.1016/0092-8674(88)90530-2

Lawrence J.B., Villnave C.A., Singer R.H.

Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line.

Cell 52:51-61(1988)

PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; PMCID=PMC452998

Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.

p53 is frequently mutated in Burkitt's lymphoma cell lines.

EMBO J. 10:2879-2887(1991)

PubMed=2052620; DOI=10.1073/pnas.88.12.5413; PMCID=PMC51883

Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.

p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)

PubMed=1325212; DOI=10.1182/blood.V80.5.1289.1289

Benjamin D., Knobloch T.J., Dayton M.A.

Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10.

Blood 80:1289-1298(1992)

PubMed=1339415; DOI=10.1002/ijc.2910520320

Middleton P.G., Miller S., Ross J.A., Steel C.M., Guy K.

Insertion of SMRV-H viral DNA at the c-myc gene locus of a BL cell line and presence in established cell lines.

Int. J. Cancer 52:451-454(1992)

PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493

Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.

Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.

FASEB J. 7:951-956(1993)

PubMed=8402660

O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T., Kohn K.W.

Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.

Cancer Res. 53:4776-4780(1993)

PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418

Jain V.K., Judde J.-G., Max E.E., Magrath I.T.

Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.

J. Immunol. 150:5418-5428(1993)

PubMed=8176200; DOI=10.4049/jimmunol.152.10.4749

Benjamin D., Sharma V., Knobloch T.J., Armitage R.J., Dayton M.A., Goodwin R.G.

B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors.

J. Immunol. 152:4749-4757(1994)

PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893

Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R., De Lord C.F.M., Clutterbuck R.D., Treleaven J.G., Powles R.L., Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D., Millar J.L., Catovsky D., Dyer M.J.S.

Deletions and rearrangement of CDKN2 in lymphoid malignancy.

Blood 85:893-901(1995)

DOI=10.11418/jtca1981.15.4_211

Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.

Identification of cell lines with variable numbers of tandem repeat (VNTR) amplified by polymerase chain reaction.

Tissue Cult. Res. Commun. 15:211-219(1996)

PubMed=8558920

Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

Leukemia 10:142-149(1996)

PubMed=8568269; DOI=10.4049/jimmunol.156.4.1626

Benjamin D., Sharma V., Kubin M., Klein J.L., Sartori A., Holliday J., Trinchieri G.

IL-12 expression in AIDS-related lymphoma B cell lines.

J. Immunol. 156:1626-1637(1996)

PubMed=9192833

Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S., Pike S.E., Gupta G., Magrath I.T., Tosato G.

Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.

Cancer Res. 57:2508-2515(1997)

PubMed=9473234; DOI=10.1182/blood.V91.5.1680

Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.

p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.

Blood 91:1680-1687(1998)

PubMed=9973220

Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G., Magrath I.T., Bhatia K.G.

Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.

Cancer Res. 59:696-703(1999)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.

Leuk. Res. 24:255-262(2000)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.

Leuk. Res. 25:275-278(2001)

PubMed=12145705; DOI=10.1038/sj.leu.2402519

Langerak A.W., Moreau E.J., van Gastel-Mol E.J., van der Burg M., van Dongen J.J.M.

Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool.

Leukemia 16:1572-1573(2002)

PubMed=16960149; DOI=10.1182/blood-2006-06-026500

Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M., Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F., Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S., Martinez-Climent J.A.

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.

Blood 109:271-280(2007)

PubMed=18357372; DOI=10.3892/or.19.4.889

Pop I., Pop L., Vitetta E.S., Ghetie M.-A.

Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein.

Oncol. Rep. 19:889-895(2008)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168

Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=21269460; DOI=10.1186/1752-0509-5-17; PMCID=PMC3039570

Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.

Initial characterization of the human central proteome.

BMC Syst. Biol. 5:17.1-17.13(2011)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22885699; DOI=10.1038/nature11378; PMCID=PMC3609867

Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L., Wright G., Shaffer A.L. 3rd, Hodson D.J., Buras E., Liu X.-L., Powell J.I., Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.M., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Nature 490:116-120(2012)

PubMed=24590883; DOI=10.1002/gcc.22161

Murga Penas E.-M., Schilling G., Behrmann P., Klokow M., Vettorazzi E., Bokemeyer C., Dierlamm J.

Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples.

Genes Chromosomes Cancer 53:497-515(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145

Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

J. Virol. 89:713-729(2015)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29892436; DOI=10.1098/rsos.172472; PMCID=PMC5990783

Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M., Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S., Satoh M., Shimizu N., Kohara A.

Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.

R. Soc. Open Sci. 5:172472-172472(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

Screening human cell lines for viral infections applying RNA-Seq data analysis.

PLoS ONE 14:E0210404-E0210404(2019)"